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Background: Previous studies indicated that affect fluctuations, the use of
antidepressant medication (ADM), as well as depression during pregnancy might have
adverse effects on offspring outcomes. The aim of the current proof-of-principle study
is to explore the effect of tapering ADM while receiving online preventive cognitive
therapy (PCT) on pregnant women and the offspring as compared to pregnant women
continuing ADM.
Objectives: We sought to compare positive and negative affect fluctuations in pregnant
women receiving online PCT while tapering ADM vs. pregnant women continuing ADM,
and to investigate if affect fluctuations in early pregnancy were related to offspring
birth weight.
Method: An experience sampling methodology (ESM)-trial ran alongside a Dutch
randomized controlled trial (RCT) and prospective observational cohort of women using
ADM at the start of pregnancy. In the ESM-trial fluctuations of positive and negative
affect were assessed in the first 8 weeks after inclusion. Recurrences of depression
were assessed up to 12 weeks post-partum, and birth records were used to assess
offspring birth weight. The RCT has been registered at the Netherlands Trial Register
(NTR4694, https://www.trialregister.nl/trial/4551).
Results: In total, 19 pregnant women using ADM at start of their pregnancy participated
in the ESM-trial. There were no significant differences in positive and negative affect
fluctuations, nor recurrence rates between women receiving PCT while tapering ADM vs.
women continuing ADM. We found no association between affect fluctuations, pre-natal
depressive symptoms, and birth weight (all p > 0.05).
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Conclusion: This explorative study showed that tapering ADM while receiving
online PCT may protect pregnant women against recurrences of depression and
affect fluctuations, without affecting birth weight. There is a high need for more
controlled studies focusing on tapering ADM with (online) psychological interventions
during pregnancy.
Keywords: pregnancy, preventive cognitive therapy, antidepressants, tapering and discontinuation, offspring,
experience sampling methodology (ESM), proof-of-principle
INTRODUCTION
Major depressive disorder (MDD) is a highly disabling and
recurrent disorder that affects people worldwide, including
pregnant women. Women with a history of mental disorders
are at increased risk of perinatal depression (1, 2). Reported
recurrence rates of MDD during pregnancy range widely from
2.5 to 68%, depending on the population, treatment, and
follow-up period (3–7). MDD and recurrences in the perinatal
period can place women and their offspring at risk of short-
and long-term psychological and somatic problems, including
low birth weight, pre-term birth, and shorter gestational age,
which in turn are associated with psychopathology at later
ages (8–10), development of MDD, anxiety, and developmental
disorders (11–15). Birthweight and gestational age can hence
be perceived as first indications of infant’s future (mental)
health. It is presumed that psychological and pharmacological
treatment of pre-natal common mental disorders can mitigate
associated adverse effects in offspring, yet strong evidence
for the prophylactic benefits of (preventive) treatment is
limited (16, 17).
Current treatments to prevent recurrences of MDD during
pregnancy include the use of antidepressants medication (ADM).
ADM use during pregnancy is estimated to be around 2–8%
for various psychiatric disorders (18–21), however, reviews
have linked pre-natal ADM use to negative offspring outcomes,
including lower birth weight, shorter gestation, development
of psychopathology, and cardiovascular problems (22–24).
Alternatively, sequentially offering a specific psychological
relapse prevention treatment after (partial) remission (i.e.,
mindfulness-based cognitive therapy [MBCT], preventive
cognitive therapy [PCT], or well-being therapy [WBT]) protects
against recurrences of MDD, when compared to active (e.g.,
ADM or treatment as usual [TAU]) or non-active (waitlist)
control groups (25–35). Psychological prevention treatments
have furthermore been demonstrated to be effective in lowering
depressive symptoms during pregnancy (17, 36), and may lower
the risk of recurrence of MDD (37). In a recent randomized
controlled trial (RCT) (38–41), we investigated the efficacy of
PCT with gradual, guided discontinuation of ADM compared
to ADM continuation among formerly depressed women
taking ADM at the start of their pregnancy. The women
(n = 44) were followed throughout pregnancy and up to 3
months post-partum to evaluate recurrences of MDD and
the potential impact of the interventions on mother and
offspring. There was no evidence that PCT with gradual
discontinuation of ADM during pregnancy altered the risk
of recurrence of MDD as compared to continuation of ADM
(41). This study provides first evidence that preventive therapy
while tapering ADM may be a viable alternative to ADM
usage for both the formerly depressed pregnant women and
their offspring.
Early identification of women at risk and subsequent
prevention of relapse or recurrence of MDD in the perinatal
period are hence of importance. Previous research showed that
certain patterns of variability of affect within individuals may
indicate that the individual is prone to depressive relapse or
recurrence (42–44). Some studies showed that low positive affect
and high negative affect were related to increased depressive
symptoms, and increased risk of recurrence of MDD (45–47). On
the other hand, a case study and a study in depressed patients
(n = 93) showed that the inertia of affect, i.e., the lack of
variability, were indicators that a person relapsed into depression
(43, 48), although this was not confirmed in a recurrently
depressed patient sample (n = 42) (49). The variability of affect
is nevertheless believed to be clinically relevant and warrants
further investigation.
Affect and affect fluctuations are indeed important to consider
in the context of pregnant women and their offspring since
previous studies showed that increased positive affect may
prevent pre-term birth, although without changing birth weight
(50), and that positive and negative affect fluctuations are
associated with poorer offspring outcomes such as disturbed
fetal physiology [e.g., decreased fetal heart rate and intrauterine
artery flow (51)]. At the same time, symptoms of depression
and anxiety, and stress levels commonly vary throughout
pregnancy (52–54), which in turn are associated with negative
affect (reported by the mother) in 1–7 year old children (55),
and delayed child development (54). These studies highlight
that fluctuations in positive and negative affect and offspring
outcomes need to be monitored, especially during relapse
prevention interventions.
Experience Sampling Methodology (ESM) (56), which has
been successfully used in previous studies (44, 47, 49), provides
the opportunity to monitor affect fluctuations and the impact
on offspring by multiple semi-random assessments through a
mobile telephone application during the day. ESM-trials allow
researchers to profoundly investigate day-to-day affect and mood
(changes) and early warning signs of depressive relapse in
pregnant women. ESM surpasses the problem of traditional
self-report questionnaires, where there is an increased risk of
a recall bias. For example, self-report questionnaires such as
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the Edinburgh post-natal depression scale, include questions
regarding mood across 1 full week, while it is known that mood
symptoms fluctuate throughout the week, or even 1 day (57). In
addition, the use of ESM permits researchers to answer research
questions by investigating less participants while gathering more
information than in traditional designs, which enables including
difficult-to-reach populations in research, like the population in
the previously described RCT (41).
The question remains whether pregnant women receiving
PCT while tapering ADM have more affect fluctuations as
compared to pregnant women continuing ADM. Furthermore,
it is currently unknown whether affect fluctuations can predict
the return of depressive symptoms or recurrence of MDD in
pregnant women, and predict offspring health (as measured in
terms of birth weight, with and without correction for gestational
age). Offspring birth weight is important to investigate due
to its relation with future developmental, mental, and somatic
disorders. Using an ESM-design alongside the previously
described RCT and observational cohort (38–41), the aims
of the current study are to (1) explore whether there are
more fluctuations in negative and positive affect in pregnant
women receiving PCT while tapering ADM vs. continuing
ADM; (2) explore whether affect fluctuations predict subsequent
recurrences and/or pre-natal depressive symptoms; and (3)
explore whether affect fluctuations predict lower offspring
birth weight.
MATERIALS AND METHODS
Design
This article focuses on the ESM-trial run alongside an RCT
and an observational cohort. Participants for the ESM-trial were
drawn from an RCT [“Stop or Go study” (39)] and a prospective,
longitudinal, observational cohort (38, 40), to investigate the
effects of PCT while tapering ADM vs. the continuation of ADM.
All studies were approved by the Medical Ethical Committee of
the Erasmus Medical Center Rotterdam, the Netherlands (MEC-
2014-505). All participants provided written informed consent
prior to participation.
The RCT protocol has been pre-registered (Netherlands
Trial Register: NTR4694) and published (39). The observational
cohort has been described in other publications (38, 40) and the
protocol has not been pre-registered, as this group of participants
was a reference group for the RCT. The ESM-trial started at a later
stage of the studies due to the development and coordination
of the mobile application, and is therefore not reported in the
protocol article.
Participants
ESM-Trial
Participants from the RCT and observational cohort were invited
to participate in the ESM-trial after providing written informed
consent for the RCT or observational cohort. Participant in-and
exclusion criteria and procedures for the RCT and observational
cohort are described below. There were no additional criteria to
participate in the ESM-trial.
RCT and Observational Cohort
To participate in the RCT or cohort, women needed to (1)
be <16 weeks pregnant; (2) use an ADM at the start of the
pregnancy, such as selective serotonin reuptake inhibitors (SSRI),
or selective noradrenaline reuptake inhibitor (SNRI); and (3) be
proficient in Dutch and/or English. Additionally, to participate
in the RCT, pregnant women needed to (1) have a history of at
least one MDD episode according to the DSM-IV Axis-I (58); (2)
be in remission or recovery, i.e., not have a diagnosis of MDD
according to the DSM-IV Axis-I criteria since at least 4 months
before participation; (3) be willing to be randomized to either
PCT with tapering of AMD (“Stop”) or continuation of ADM
(“Go”); and (4) have a singleton pregnancy.
Procedures
ESM-Trial
All participants in the RCT and observational cohort were invited
to participate in the ESM-trial. Inclusion for the ESM-trial was
from August 2016 to February 2018. The ESM-trial started
immediately after the baseline assessments and (when applicable)
randomization. As a result, the assessments were conducted at
the same time as when the participants received PCT and tapered
ADM, or continued ADM.
The ESM-trial consisted of questions that were sent in the
first 8 weeks of study participation through the mobile telephone
with the use of a pre-installed study application using the
Tempest platform (59). This application was programmed on
the participants’ own phone, or on a study-smartphone that
was available during study participation. It was programmed
to send pre-defined questions 5 days a week, 5 times a day,
for 8 consecutive weeks. The triggers were set semi-randomly
between 9:00 a.m. and 7:00 p.m., triggering once every 100min,
including a pause of 10min minimum between triggers. Time to
complete the questions was 1–2min. Participants were instructed
to respond to the trigger as soon as possible. To monitor reasons
for non-response, a research assistant contacted the participants
to discuss problems or questions regarding the application.
RCT and Observational Cohort
Participants were recruited between April 2015 and February
2018 during their first pre-natal visits at the midwifery practices
or hospitals in the Netherlands, through general practitioners,
psychiatrists, or through advertisements in (social) media. After
study researchers received contact information of potential
eligible pregnant women, the study researchers counseled the
women about the RCT and the observational cohort. After the
counseling and a waiting period to think about participation,
pregnant women decided to either (1) not participate; (2)
participate in the RCT; or, (3) participate in the observational
cohort. After this decision and written informed consent, there
was a baseline assessment by means of a structured clinical
interview through telephone [SCID-I DSM-IV (58)], and a self-
report questionnaire. If participants met inclusion criteria and
were willing to participate in the RCT, they were randomized
into one of the two groups: PCT with tapering of ADM (“Stop”)
or continuation of ADM (“Go”). Alternatively, the pregnant
woman started participating in the observational cohort, where
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women decided themselves which relapse prevention strategy
they wanted to use. Hereafter, women were assessed with
questionnaires and interviewed at 24 and 36 weeks of pregnancy,
and 4 and 12 weeks after the due-date. See Figure 1 for a
flowchart of all studies.
Interventions
PCT and Tapering ADM
Women assigned to the “Stop” -group received online PCT
and tapered ADM. The PCT was provided by trained
psychologists and consisted of 8 weekly individual sessions
using an online telehealth app. In short, PCT uses techniques
focused on dysfunctional beliefs and schema using cognitive
challenging techniques, including phantasy (activation of positive
network), enhance the recall of specific memories of positive
experiences, positive feelings and thoughts, and formulating
relapse prevention strategies (60). To taper the ADM, the woman
was referred to a trained psychiatrist or general practitioner who
then guided the tapering. Tapering schedule was based upon
an expert-based discontinuation protocol, individual preferences,
and drug characteristics. Participants were not allowed to receive
another form of psychotherapy on a regular basis during PCT,
i.e., first 8 weeks (during the ESM-trial).
Continuation of ADM
Pregnant women who were assigned to the “Go” -group
continued the use of ADM as instructed by their prescribing
doctor (care as usual).
Observational Cohort
Women in the observational cohort decided themselves which
prevention strategy they used (care as usual). This therefore
includes women who tapered ADM without PCT.
Measurements
A full overview of this schedule and all assessments can be found
in the protocol article (39).
Clinical Diagnosis
Absence and history of MDD at the start of, and relapse and
recurrence of MDD throughout study participation was assessed
with the SCID-I for DSM-IV disorders (58) up to 12 weeks post-
partum. Comorbidities on the Axis-I scale were assessed with the
SCID-I as well.
Experience Sampling Methodology
The questions consisted of 25 items, including questions
regarding positive and negative affect. The questions were
derived from previous research (49) and are based upon the
positive and negative affect schedule (PANAS) (61).1
Assessments
Participants’ characteristics were assessed at baseline, including
age, parity, and ADM usage. At baseline, and 24- and 36-
weeks of pregnancy, the Edinburgh post-natal depression scale
[EPDS (62)] for depressive symptoms, and the state-trait anxiety
1A full overview of the ESMmicro-study questions is available upon request.
inventory [STAI (63)] for anxiety symptoms were assessed. The
positive and negative affect scale [PANAS (61)] was used to assess
different affective states of the participants at baseline, and 24-
and 36-weeks of pregnancy. In addition, birth weight, gestational
age and pregnancy-related complications were collected. In
the RCT, birth outcomes were obtained from the reports
from midwives and gynecologists. Participants in the cohort
provided this information themselves during the 4 weeks post-
partum assessment.
Statistical Plan
To exploratively analyze differences in affect fluctuations during
the first 8 weeks of study participation between the PCT
while tapering ADM group and the continuation of ADM
group, the ESM-trial data was used. An average positive
affect and negative affect score was calculated for each reply
to the trigger, minimizing the number of separate variables.
That way, there was one score for each trigger for both
positive and negative affect. Participants were excluded if they
responded to <4 triggers in total, but were allowed to have
missing data. Missing data was not imputed. To estimate
individual affect fluctuations, an individual linear regression
equation was calculated using participants’ average scores on
the positive and negative affect items. For this individual linear
regression equation, the dependent variable was the mean affect
score for each trigger, and elapsed time was the independent
variable. The individual beta coefficient, the coefficient of
determination (R2), and one minus R2 (as a measure of
fluctuations) for both positive and negative affect were saved
for each participant and used in subsequent analyses. The
responses and individual regression lines were plotted for each
individual, to visually inspect patterns of positive and negative
affect fluctuations.
For the analyses, the group differences in positive and
negative affect fluctuations (ESM-trial data), with and without
correction for depressive symptoms (assessed with the EPDS),
and number of recurrences were analyzed if feasible. Second,
three separate linear regression analyses were conducted; to (1)
predict depressive symptoms with ESM positive and negative
affect fluctuations; (2) predict recurrences with ESM positive
and negative affect fluctuations; and (3) predict birth weight
with ESM positive and negative affect fluctuations corrected
for pre-natal depressive symptoms. All regression analyses were
corrected for number of previous episodes, as this was used to
stratify the randomization in the RCT sample and is a known
predictor of depressive recurrences (64).
RESULTS
Overall, 478 pregnant women were referred to the studies for
counseling, of whom 146 were eligible to participate (n = 44
participated for the RCT; n = 102 for the observational cohort).
Among these participants, 24 women agreed to participate in
the ESM-trial. See Figure 1 for a flow-chart. Sufficient data from
19 women were available for the analyses, including 12 RCT
participants of whom eight received PCT and tapered the ADM,
and four continued ADM usage. Seven participants where from
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FIGURE 1 | Flow chart of study participation and exclusion (reasons). RCT, Randomized controlled trial; RCT Stop, RCT group receiving preventive cognitive therapy
while tapering ADM; RCT Go, RCT group continuing ADM; ADM, antidepressant medication; ESM, experience sampling methodology.
the observational cohort, of whom six continued the use of
ADM, and one tapered without additional relapse prevention
intervention. An overview of baseline characteristics is displayed
in Table 1, and the study flow-chart including reasons for
drop-out is shown in Figure 1. The results of the follow-up
measurements are reported in Table 2.
ESM-Trial Results (n = 19)
In total, 2 out of 19 women participating in the ESM-trial had a
recurrence of MDD during the study period. Mean positive affect
score across groups was 48.56 (SD = 16.61), and mean negative
affect was 20.51 (SD = 13.35). There was no significant group
effect (RCT women tapering ADM vs. RCT women continuing
ADM) on positive or negative affect fluctuations (positive affect:
F(1,9) = 1.85, p = 0.20; negative affect: F(1, 9) = 0.44, p = 0.52).
When including women from the observational cohort into the
ESM-trial analyses, this effect between tapering and continuing
ADM remained non-significant (positive affect: F(1, 15) = 0.16, p
= 0.69; negative affect: F(1, 15) = 3.86, p = 0.07). Correcting the
analyses for depressive symptoms at baseline did not change the
main results (positive affect: F(1, 14) = 0.21, p = 0.65; negative
affect: F(1, 14) = 3.45, p = 0.08). As an example of the ESM-
trial outcomes, Figure 2 displays the positive and negative affect
scores for a pregnant woman who received PCT and tapered
ADM (RCT participant), and a pregnant woman who continued
ADM (cohort participant).
Linear regression analyses indicated that positive or negative
affect fluctuations did not significantly predict depressive
symptoms at 36 weeks pregnancy (positive affect β = 0.22,
95% CI = −15.84, 37.20, p = 0.40; negative affect β = −0.26,
95% CI = −22.55, 7.96, p = 0.32). Furthermore, there was
no significant relationship between affect fluctuations and birth
weight (positive affect β =−0.08, 95% CI =−3,083.36, 2,310.35,
p= 0.76; negative affect β = 0.18, 95% CI =−1,081.73, 2,052.82,
p = 0.51) or corrected birth weight for gestational age (positive
affect β = 0.17, 95% CI = −120.28, 217.74, p = 0.54; negative
affect β = 0.18, 95% CI = −67.96, 128.48, p = 0.52). There
was an insufficient number of recurrences in the ESM-trial to
investigate and test the relationship between affect fluctuations
and recurrences of MDD.
Main RCT and Cohort Results
In the main trials (RCT and observational cohort), 13 women
had a recurrence of MDD during the study period (8.9%). The
number of recurrences did not significantly differ between the
groups in the main RCT (PCT with tapering ADM n = 3 vs.
ADM continuation n = 3), but did in the full group (taper
ADM with or without PCT n = 8 vs. ADM continuation n =
5; X2(1)= 8.60, p= 0.003).
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TABLE 1 | Baseline participant characteristics.
ESM-trial
(n = 19)
RCT Stop
(n = 24)
RCT Go
(n = 20)
Cohort
(n = 94)
Mean age in years (SD) 32.3 (4.8) 31.6 (5.3) 31.4 (4.3) 31.3 (4.3)
Nulliparous (%) 2 (15) 3 (20) 1 (8) 7 (16)
Born in the Netherlands (%)a 18 (100) 22 (100) 14 (87) 89 (99)
Marital status
Single (%) 1 (5.3) 1 (4) 1 (5) 3 (3)
Partner, living apart (%) 1 (5.3) 1 (4) 1 (5) 5 (5)
Married or cohabiting(%) 17 (89) 22 (92) 17 (89) 86 (91)
Smoking (%) 2 (10) 3 (12) 1 (5) 5 (5)
Education
Primary school or Secondary education (%) 0 (0) 1 (4) 1 (5) 4 (4)
Vocational or Pre-university education (%) 8 (44) 11 (46) 8 (40) 27 (30)
Higher education (%) 10 (56) 12 (50) 11 (55) 58 (65)
Duration ADM usage, in months (SD) 72.9 (59.0) 56.0 (50.0) 50.6 (38.0) 72.3 (65.0)
Number of previous MDD episodes (SD) 1.9 (1.0) 2.2 (1.2) 1.9 (1.5) 1.9 (1.5)
Comorbid DSM-IV Axis-I disorders, yes (%) 7 (37) 9 (37) 7 (35) 28 (29)
Mean EPDS score (SD) 5.5 (3.3) 6.3 (3.6) 4.5 (3.1) 6.5 (4.4)
Mean STAI score
STAI—state (SD) 33.3 (9.1) 34.0 (8.2) 32.6 (7.6) 35.2 (9.5)
STAI—trait (SD) 39.5 (7.8) 39.3 (7.1) 35.4 (6.5) 40.4 (9.6)
Mean PANAS score
Positive affect (SD) 2.1 (0.6) 2.0 (0.6) 2.2 (0.7) 2.0 (0.7)
Negative affect (SD) 0.7 (0.7) 0.8 (0.7) 0.5 (0.5) 0.9 (0.7)
Not all information is available for each participant, resulting in small variations of percentages. Numbers are rounded. RCT, Randomized controlled trial; RCT Stop, RCT group receiving
preventive cognitive therapy while tapering ADM; RCT Go, RCT group continuing ADM; ADM, antidepressant medication; ESM, experience sampling methodology; HRSD-17, Hamilton
Rating Scale for Depression−17 items; MDD, major depressive disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders fourth edition; EPDS, Edinburgh post-natal
depression scale, STAI, state-trait anxiety inventory; PANAS, positive and negative affect scale.
aChi-square indicates significant differences between RCT Stop, RCT Go, and Cohort group (p = 0.02).
TABLE 2 | Group results follow-up measurements and EMA–trial.
ESM-trial (n = 19) RCT Stop (n = 8) RCT Go (n = 4) Cohort (n = 7)
No. of recurrences 1 0 1
Mean number of responses (SD) 40.9 (34.4) 19.2 (13.9) 48.9 (27.4)
Positive affect
B 0.07 (0.31) 0.25 (0.44) −0.04 (0.12)
R2 0.09 (0.13) 0.19 (0.12) 0.03 (0.05)
Negative affect
B 1.06 (3.15) −0.25 (0.49) 0.10 (0.20)
R2 0.21 (0.26) 0.11 (0.18) 0.09 (0.13)
Stress 31.79 (14.16) 23.35 (11.65) 25.52 (31.82)
Main trial results (n = 121) RCT Stop (n = 19) RCT Go (n = 19) Cohort (n = 83)
Mean birthweight, in gram (SD) 3,632.1 (474.3) 3,369 (422.9) 3,382.6 (463.2)
Mean gestational age, in days (SD) 277 (6.9) 275 (5.5) 275 (9.3)
Mean BW for GA, percentile (SD) 43.4 (33.7) 41.6 (31.2) 48.2 (29.8)
Numbers are rounded. RCT, Randomized controlled trial; RCT Stop, RCT group receiving preventive cognitive therapy while tapering ADM; RCT Go, RCT group continuing ADM; ADM,
antidepressant medication; ESM, experience sampling methodology; BW, birthweight; GA, gestational age; Mean BW for GA, birthweight corrected for gestational age.
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FIGURE 2 | Two participant examples of positive and negative affect fluctuations in the ESM-trial.
DISCUSSION
The aim of the current study was to explore the effect of tapering
ADM in pregnant women while receiving PCT as compared to
pregnant women continuing ADM. In this proof-of-principle
study, there were no indications that pregnant women who
received PCT and tapered ADM showed more affect fluctuations
or recurrences than women continuing ADM. To our knowledge
this is the first study to show individual fluctuations of positive
and negative affect and depression recurrence rates in an RCT
and observational cohort of pregnant women using ADM at the
start of their pregnancy.
Although the study had an explorative nature with a relatively
small group of women, there was a large amount of individual
responses (ranging from 6 to 105 responses per individual).
The results of the ESM-trial indicate that women receiving PCT
while tapering ADM show similar patterns of fluctuations in
positive and negative affect throughout pregnancy, as women
continuing ADM. This may be due to the effects of PCT which
targets cognitive vulnerabilities by challenging dysfunctional
beliefs and schema’s, activating positive networks, and enhancing
the memory of positive experiences (28). PCT therefore partially
targets emotion regulation (28), by changing the way a person
processes and regulates emotion-related information (65). In
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addition, a previous study showed that people who received
PCT were less affected by daily hassles, which may have led
to a reduced risk of recurrence in comparison to care as usual
(66). Potentially, women receiving this preventive psychotherapy
therefore did not show increased fluctuations in their affect
or inertia, as they were able to regulate their emotions and/or
process daily hassles better, thereby potentially lowering the risk
of recurrence of MDD.
This is in contrast to a previous study among formerly
depressed remitted participants that showed that people
receiving PCT while tapering ADM had a slightly higher risk of
recurrence in the first 4 months of tapering, indicating there may
have been a withdrawal effect in these participants due to various
reasons [e.g., imbalance due to withdrawal symptoms, or fear of
recurrence; (27)]. In the current study, there was no difference
in the number of recurrences, as well as no difference in positive
and negative affect fluctuations in the group of women receiving
PCT while tapering ADM. This might imply that there was
none or less emotional withdrawal or discontinuation symptoms
(67, 68), or fear of recurrences, in this group. An explanation for
this difference may be that women learned to regulate emotions
with the help of PCT (28, 65). The ESM-trial was conducted
during the time that women tapered ADM and received PCT.
Alternatively, unknown factors caused by the pregnancy itself
might have protected the women from fluctuating more in affect
while tapering ADM vs. continuation of ADM. This alternative
explanation is supported by the fact that the few recurrences of
depression in the main RCT primarily occurred in the first 3
months post-partum.
Another potential explanation for the absence of significant
differences in affect fluctuations between PCT while tapering
ADM vs. continuation of ADM, may be the low recurrence
rates among the participants, with no significant differences
in recurrence rates between women receiving PCT while
tapering ADM and women continuing ADM. Previous studies
investigating recurrence rates in pregnant women discontinuing
ADM are scarce and have produced conflicting results. Although
previous research found even lower recurrence rates in a group
of pregnant women with a history of MDD [2.5% (69)], another
study showed an increased risk of recurrence after pre-natally
tapering ADM compared to continuation of ADM [68% (3)]. Yet
another study found comparable recurrence rates in both groups
[16% (6)]. One of the main differences between these studies is
the selection of specific populations using different prevention
strategies. For example, the pregnant women from previous
studies had a history of more severe MDD and/or more or severe
comorbid psychopathology, tapered ADM without guidance or
complementary psychotherapy, or were actively seeking help and
therefore may have had subsyndromal depressive symptoms for
which they needed help. In contrast, the current study focused on
the results of the RCT and cohort with stable remitted previously
depressed pregnant women.
There were also no differences in the birth weight of offspring
from women tapering or continuing ADM. Birth weight may
already be affected by ADM use in early pregnancy, as previous
reviews indicated (23). On the other hand, psychotherapy may
likewise positively or negatively influence birth weight. A recent
meta-analysis found that birth weight could be negatively or
positively affected when pregnant women with common mental
disorders received psychotherapy, depending on the disorder
and type of treatment (16). The absence of a direct influence
of affect fluctuations on birth weight does not necessarily mean
that these fluctuations do not affect the offspring. It may be the
case that adverse effects are expressed later in life. For example,
one study showed that levels of maternal mood symptoms
during pregnancy predicted negative affect in the offspring at age
one, two, and seven (55), and another study demonstrated that
elevated anxiety symptoms increased the risk of offspring having
delayed development at the age of 3 years (54). Alternatively, the
absence of a link between affect fluctuations and birth weight can
be explained by the small sample size.
Despite several strengths of the current study, being
the first proof-of-principle ESM RCT to investigate tapering
ADM in pregnant women while receiving a psychotherapeutic
intervention as compared to continuation of ADM, there were
several limitations that need to be addressed. First, the small
sample size in the ESM-trial prevented us from drawing firm
conclusions about the potential role of affect fluctuations.
However, 800 datapoints have been gathered enabling us to
analyse continuous fluctuations in affect with a minimal risk of
recall bias [e.g., (57)], and more details regarding the effect of
tapering ADM with PCT among pregnant women. Second, the
low recurrence rates and low variation of depressive symptoms
throughout pregnancy may have minimized the likelihood
of detecting clinically meaningful associations. However, low
recurrence rates while tapering ADM might also indicate that
tapering ADM in pregnancy has limited risks while receiving
PCT. Lastly, the participant group may have comprised relatively
healthy women with low levels or residual depressive symptoms,
whichmay have put them at low risk of recurrence. Although, our
sample at baseline on average had two previous MDD episodes,
comparable to other depression-related study samples. Due to
these limitations, the results of this proof-of-principle study
must be interpreted with caution, and a replication of the study
is needed.
Overall, the current study and explorative analyses provide no
first indications that pregnant women show more fluctuations in
positive/negative affect, nor recurrences, when they taper ADM
and receive PCT compared to when women continue ADM. This
is supported by the results of the main trial, where the pregnant
women in both groups had a comparable risk of relapse (41).
Pregnant womenmay not be at increased risk of recurrence when
they taper ADM, or put their child at risk of negative outcomes
such as lower birth weight. Future research should explore
recurrence risk in larger (international) samples and individual
pathways of affect fluctuations and MDD recurrence in pregnant
women with a history of MDD who use ADM. Moreover, the
effects and effectiveness of relapse prevention treatments for both
mother and child need to be further investigated. More research
is needed to investigate whether indeed the PCT led to the
current results.
To conclude, the current proof of principle study provided a
first indication that tapering ADMwith the guidance of PCTmay
indeed protect pregnant women against recurrence of depression
and affect fluctuations, without evident negative effects on birth
weight of the offspring.
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